Thursday, July 23, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
Who Could Afford to Be Late
Within about 24 hours this week, the surgical robotics field delivered two verdicts that read like opposite ends of the same story.
On Tuesday, shareholders of Vicarious Surgical voted to dissolve the company and hand its assets to a creditor trust — an assignment for the benefit of creditors, the orderly alternative to bankruptcy. On Wednesday, the FDA granted De Novo authorization to Johnson & Johnson’s Ottava, clearing the first table-integrated soft-tissue robot for general surgery in the United States.
Both programs ran years past their own timelines. The difference showed up in what happened next.
Vicarious was not a fringe player. Founded in 2014, it went public in 2021 through a SPAC merger that valued it at $1.1 billion, and it raised hundreds of millions from investors that included Bill Gates. Its single-port system — miniaturized arms and a camera threaded through one incision, built to put the surgeon inside the abdomen — was novel enough to become the first surgical robot ever to earn the FDA’s breakthrough device designation.
It also missed, repeatedly. The system slipped against its stated timelines. A planned clinical trial was scrapped. Parts of the design were outsourced to conserve cash. The company lost its NYSE listing earlier this year and moved to the over-the-counter market. When it went looking for fresh capital or a buyer this spring, it found neither. As of early March it employed 26 people. In its final filings, the board told shareholders they were unlikely to receive anything at all — even as terminated executives were set to collect severance packages north of half a million dollars each.
Ottava is the other end. J&J’s robotics ambitions run back through Verb Surgical and the acquisition of Auris Health, and Ottava itself was delayed repeatedly against publicly stated targets. But a parent that just beat $25 billion in quarterly sales does not face a going-concern deadline when a program runs long. It rewrites the date and keeps paying the engineers.
That comparison is worth exactly what it costs, which is not much. Almost nobody reading this is J&J, and “have a $400 billion parent” is not a strategy. The useful case sits between the two, and surgical robotics has already run it.
Asensus Surgical — formerly TransEnterix — hit the same wall Vicarious did. Its Senhance platform was commercial but small, its next-generation Luna system was years from clearance, and cash was the binding constraint. It did not liquidate. In August 2024 it was acquired by Karl Storz for $0.35 a share in cash. The technology found a home; more than 200 employees came along; the buyer talked publicly about accelerating Luna.
Twenty-two months later, Karl Storz ended development of the standalone platform, began phasing out Senhance, retired the Asensus brand, and filed notice of 108 layoffs in North Carolina. What it kept was the software engineering, the clinical data, and the AI work — folded into its own imaging and OR-integration roadmap.
So the three exits are not survive, get rescued, or die. They are: absorb the delay yourself, sell into someone who will decide later which parts of you were worth buying, or liquidate. Only the first is fully in your control, and only the largest companies in the industry have it.
This is the part worth sitting with. Asensus is the good outcome in that set, and the good outcome still ended with the platform discontinued and the brand retired. It preserved the people and the IP. It did not preserve the company’s plan. And the price — thirty-five cents — was set by a buyer who knew exactly how much runway was left on the other side of the table.
For anyone running a capital-intensive program on a regulatory timeline, that reframes the planning question. It is not how long the runway is against the current schedule; the current schedule is the optimistic case, and slippage is the base case, not the downside. The question is what your position looks like at the moment the money gets tight — because that moment is when the exit gets chosen, and whoever has cash at that point sets the terms.
Vicarious had the idea first. Asensus had a buyer. J&J had the room to be late. Three companies, one category, three different answers to the same missed deadline.
SPONSORED BY RŌG HEALTH
Where does your commercialization actually stand?
Two minutes to find out.
Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.